Key result
Bivalirudin significantly decreased the risk of net adverse clinical events (HR 0.75) compared to unfractionated heparin in patients undergoing elective percutaneous coronary intervention.
Why the study?
While bivalirudin reduces ischemic and hemorrhagic events in primary PCI, its long-term safety and efficacy in patients undergoing elective PCI remained unclear.
Does bivalirudin reduce net adverse clinical events and bleeding compared to unfractionated heparin in patients undergoing elective PCI?
Observational (n=2,670)
Yes
Does bivalirudin reduce net adverse clinical events and bleeding compared to unfractionated heparin in patients undergoing elective PCI?
Hazard Ratio: 0.75 (95% CI 0.58–0.96)
Absolute Event Rate: 9.3% vs 12.7%
p-value: p=0.021
No takes yet. Share an insight, caveat, or question.
Bivalirudin was associated with lower NACE and bleeding versus UFH in elective PCI; leaves open whether randomized trials will confirm long-term benefit.
Li et al. (2023) conducted an observational in Elective percutaneous coronary intervention (n=2,670). Bivalirudin vs. Unfractionated heparin (UFH) with or without glycoprotein IIb/IIIa inhibitors (GPI) was evaluated on Net adverse clinical events (NACE) (HR 0.75, 95% CI 0.58-0.96, p=0.021). Bivalirudin significantly decreased the risk of net adverse clinical events (HR 0.75) compared to unfractionated heparin in patients undergoing elective percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: